{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:35:34Z","timestamp":1791858934110,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pcl.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T23:24:40Z","timestamp":1532042680000},"page":"827-854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Complications of Treatments for Pediatric Rheumatic Diseases"],"prefix":"10.1016","volume":"65","author":[{"given":"Gloria C.","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2018.04.008_bib1","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.171087","article-title":"Barriers to adherence in juvenile idiopathic arthritis: a multicenter collaborative experience and preliminary results","author":"Favier","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.pcl.2018.04.008_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/1471-2407-14-634","article-title":"Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis","volume":"14","author":"Kok","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pcl.2018.04.008_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212613","article-title":"Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors","author":"Beukelman","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.pcl.2018.04.008_bib4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","article-title":"Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents","volume":"64","author":"Nordstrom","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.08570814","article-title":"Immunosuppressive medications","volume":"11","author":"Wiseman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","article-title":"Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?","volume":"48","author":"McLean-Tooke","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11926-016-0561-4","article-title":"Infection and lupus: which causes which?","volume":"18","author":"Doaty","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.pcl.2018.04.008_bib9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","article-title":"Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies","volume":"22","author":"Danza","year":"2013","journal-title":"Lupus"},{"issue":"Suppl 3","key":"10.1016\/j.pcl.2018.04.008_bib10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar4174","article-title":"Use of NSAIDs in treating patients with arthritis","volume":"15","author":"Crofford","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0976-500X.107684","article-title":"Prescribing pattern of gastroprotective agents with non-steroidal anti-inflammatory drugs","volume":"4","author":"Manohar","year":"2013","journal-title":"J\u00a0Pharmacol Pharmacother"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12882-017-0673-8","article-title":"Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis","volume":"18","author":"Zhang","year":"2017","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A\u00a0practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib15","doi-asserted-by":"crossref","first-page":"e0170259","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long-course oral corticosteroids in children","volume":"12","author":"Aljebab","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pcl.2018.04.008_bib16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/acr.23219","article-title":"Serious infection rates among children with systemic lupus erythematosus enrolled in Medicaid","volume":"69","author":"Hiraki","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib17","first-page":"2018","article-title":"High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis","volume":"27","author":"Kimura","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.pcl.2018.04.008_bib18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00247-012-2487-y","article-title":"Ultrasound-guided corticosteroid injection therapy for juvenile idiopathic arthritis: 12-year care experience","volume":"42","author":"Young","year":"2012","journal-title":"Pediatr Radiol"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients","volume":"76","author":"Caplan","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib20","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.pcl.2018.04.008_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/TCRM.S154745","article-title":"Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis","volume":"14","author":"Vena","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.pcl.2018.04.008_bib23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/acr.21697","article-title":"Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry","volume":"64","author":"Klein","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.pcl.2018.04.008_bib24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.pcl.2018.04.008_bib25","first-page":"1113","article-title":"Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry","volume":"34","author":"Horneff","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pcl.2018.04.008_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-018-4005-6","article-title":"Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole","author":"Kwon","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.pcl.2018.04.008_bib28","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3899\/jrheum.090482","article-title":"Monitoring methotrexate toxicity in juvenile idiopathic arthritis","volume":"36","author":"Kocharla","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"5 Suppl 61","key":"10.1016\/j.pcl.2018.04.008_bib29","first-page":"S65","article-title":"Long-term safety of methotrexate in the treatment of rheumatoid arthritis","volume":"28","author":"Yazici","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"10.1016\/j.pcl.2018.04.008_bib30","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.pcl.2018.04.008_bib31","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2165\/00003495-200565130-00008","article-title":"Sulfasalazine: a review of its use in the management of rheumatoid arthritis","volume":"65","author":"Plosker","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000312632","article-title":"Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole","volume":"153","author":"Zawodniak","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for Sjogren's disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.pcl.2018.04.008_bib35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/BOR.0000000000000500","article-title":"Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update","volume":"30","author":"Abdulaziz","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"20","key":"10.1016\/j.pcl.2018.04.008_bib37","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib38","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3899\/jrheum.141650","article-title":"Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: a systematic review and network metaanalysis","volume":"42","author":"Tian","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.pcl.2018.04.008_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.autrev.2016.07.014","article-title":"Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation","volume":"15","author":"Levy","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.pcl.2018.04.008_bib40","article-title":"Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study","author":"Alami","year":"2017","journal-title":"Therapie"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib41","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pcl.2018.04.008_bib42","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Hoskova","year":"2017","journal-title":"Physiol Res"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/annrheumdis-2012-202099","article-title":"Lymphoma risk in systemic lupus: effects of disease activity versus treatment","volume":"73","author":"Bernatsky","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib46","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.pcl.2018.04.008_bib47","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/art.21263","article-title":"Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus","volume":"52","author":"Somers","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.pcl.2018.04.008_bib48","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00467-014-2897-1","article-title":"Fertility preservation in patients receiving cyclophosphamide therapy for renal disease","volume":"30","author":"Gajjar","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib49","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.pcl.2018.04.008_bib53","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.pcl.2018.04.008_bib54","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British society for paediatric and adolescent rheumatology etanercept cohort study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib56","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1209","article-title":"Infectious complications with the use of biologic response modifiers in infants and children","volume":"138","author":"Davies","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/ar4541","article-title":"Tumor necrosis factor: is it time to change the name?","volume":"16","author":"Pisetsky","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib58","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.pcl.2018.04.008_bib59","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9636","key":"10.1016\/j.pcl.2018.04.008_bib60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pcl.2018.04.008_bib61","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3899\/jrheum.151389","article-title":"Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis","volume":"43","author":"Birolo","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"25","key":"10.1016\/j.pcl.2018.04.008_bib62","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/14712598.2016.1150997","article-title":"Tocilizumab for treating juvenile idiopathic arthritis","volume":"16","author":"Turnier","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib64","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-Rio","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib65","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.pcl.2018.04.008_bib69","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/imj.12002","article-title":"Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra","volume":"42","author":"Loh","year":"2012","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib70","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3899\/jrheum.121098","article-title":"Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome","volume":"40","author":"Kahn","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.pcl.2018.04.008_bib71","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.pcl.2018.04.008_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of the phase 3\u00a0United States BLISS-76 trial","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.pcl.2018.04.008_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2018.01.001","article-title":"Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus","author":"Oon","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib75","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.pcl.2018.04.008_bib77","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/ijd.13691","article-title":"Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases","volume":"56","author":"Havmose","year":"2017","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.pcl.2018.04.008_bib78","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/imj.13637","article-title":"Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients","volume":"47","author":"Peer","year":"2017","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib80","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/tpj.2015.53","article-title":"Paradoxical psoriasiform reactions to anti-TNFalpha drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib81","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.pcl.2018.04.008_bib82","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3899\/jrheum.140472","article-title":"Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics","volume":"42","author":"Barthel","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.pcl.2018.04.008_bib83","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the swiss inflammatory bowel disease cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.pcl.2018.04.008_bib84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","article-title":"Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease","volume":"39","author":"Gaujoux-Viala","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib85","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.pcl.2018.04.008_bib86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbspin.2017.01.002","article-title":"Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: data from the French registry REGATE","volume":"85","author":"Terreaux","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib87","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3899\/jrheum.111347","article-title":"Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry","volume":"39","author":"Thomas","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.pcl.2018.04.008_bib88","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2217\/fvl.10.12","article-title":"JC virus-induced progressive multifocal leukoencephalopathy","volume":"5","author":"Saribas","year":"2010","journal-title":"Future Virol"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib89","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaci.2017.02.013","article-title":"Biologic response modifiers: indications, implications, and insights","volume":"139","author":"Davis","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.pcl.2018.04.008_bib90","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib91","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.pcl.2018.04.008_bib92","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrrheum.2013.95","article-title":"Vaccinations in juvenile chronic inflammatory diseases: an update","volume":"9","author":"Silva","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.pcl.2018.04.008_bib93","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-202561","article-title":"Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study","volume":"73","author":"Stoof","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.pcl.2018.04.008_bib94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11926-015-0519-y","article-title":"Vaccinations in paediatric rheumatology: an update on current developments","volume":"17","author":"Groot","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"21","key":"10.1016\/j.pcl.2018.04.008_bib95","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","article-title":"Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment","volume":"35","author":"Groot","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.pcl.2018.04.008_bib96","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1473-3099(08)70231-7","article-title":"Rotavirus vaccines: viral shedding and risk of transmission","volume":"8","author":"Anderson","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.pcl.2018.04.008_bib97","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/infdis\/jir139","article-title":"Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization","volume":"203","author":"Pierson","year":"2011","journal-title":"J\u00a0Infect Dis"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395518300476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395518300476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T07:50:00Z","timestamp":1604649000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395518300476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0031395518300476"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2018.04.008","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications of Treatments for Pediatric Rheumatic Diseases","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}